



7 March 2023

LungLife AI, Inc.
(the “Company” or “LungLife”)

Nodule evaluation using LungLB® projected to be cost-effective in US healthcare system

Data strongly support payor coverage of indeterminate lung nodule evaluation using LungLB® in peer-reviewed publication in the Journal of Medical Economics.

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that further to its announcement on 27 February 2023, the final version of the health economics publication is now available. There have been no changes to the results or conclusions, which show LungLB® is projected to be a cost-effective solution for US insurers covering individuals with indeterminate lung nodules.

The publication can now be accessed here: [Journal of Medical Economics Vol 26](#)

For further information please contact:

LungLife AI, Inc.
Paul Pagano, CEO
David Anderson, CFO

www.lunglifeai.com
Via Walbrook PR

Investec Bank plc (Nominated Adviser & Broker)
Virginia Bull / Cameron MacRitchie / Lydia Zychowska

Tel: +44 (0)20 7597 5970

Walbrook PR Limited
Stephanie Cuthbert / Alice Woodings / Phillip Marriage

Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

Our Purpose is to be a driving force in the early detection to lung cancer. Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.